Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma

NCT01467986 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

130

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma Recurrent

Interventions

DRUG: Dasatinib
DRUG: Rapamycin
DRUG: Irinotecan
DRUG: Temozolomide
DRUG: Irinotecan
DRUG: Temozolomide

Sponsor

University of Regensburg